DK4108259T3 - Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf - Google Patents
Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf Download PDFInfo
- Publication number
- DK4108259T3 DK4108259T3 DK22178117.2T DK22178117T DK4108259T3 DK 4108259 T3 DK4108259 T3 DK 4108259T3 DK 22178117 T DK22178117 T DK 22178117T DK 4108259 T3 DK4108259 T3 DK 4108259T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- procedure
- concentration
- therapeutic products
- therapeutic
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
- B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/16—Feed pretreatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/16—Flow or flux control
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60909204P | 2004-09-09 | 2004-09-09 | |
US11/220,362 US20060051347A1 (en) | 2004-09-09 | 2005-09-06 | Process for concentration of antibodies and therapeutic products thereof |
EP10009914.2A EP2292636B9 (en) | 2004-09-09 | 2005-09-08 | Process for concentration of antibodies and therapeutic products thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK4108259T3 true DK4108259T3 (da) | 2024-03-11 |
Family
ID=35996499
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05806393.4T DK1786830T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til koncentration af antistoffer og terapeutiske produkter deraf |
DK22178117.2T DK4108259T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
DK10009914.2T DK2292636T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
DK20200642.5T DK3805248T5 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
DK22178156.0T DK4104859T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05806393.4T DK1786830T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til koncentration af antistoffer og terapeutiske produkter deraf |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10009914.2T DK2292636T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
DK20200642.5T DK3805248T5 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
DK22178156.0T DK4104859T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
Country Status (33)
Country | Link |
---|---|
US (6) | US20060051347A1 (da) |
EP (5) | EP4108259B1 (da) |
JP (2) | JP5210633B2 (da) |
KR (2) | KR101528970B1 (da) |
CN (3) | CN102911268A (da) |
AR (1) | AR050641A1 (da) |
AU (1) | AU2005285243C1 (da) |
BR (1) | BRPI0515649B8 (da) |
CA (1) | CA2577317C (da) |
DK (5) | DK1786830T3 (da) |
EC (1) | ECSP077282A (da) |
ES (5) | ES2968070T3 (da) |
FI (4) | FI4104859T3 (da) |
GT (1) | GT200500254A (da) |
HK (2) | HK1101249A1 (da) |
HU (3) | HUE065025T2 (da) |
IL (2) | IL181372A (da) |
LT (4) | LT2292636T (da) |
MA (1) | MA28991B1 (da) |
MX (2) | MX342788B (da) |
MY (2) | MY150549A (da) |
NO (1) | NO333660B1 (da) |
NZ (1) | NZ553239A (da) |
PE (1) | PE20060816A1 (da) |
PL (5) | PL2292636T3 (da) |
PT (5) | PT3805248T (da) |
RU (1) | RU2390524C2 (da) |
SG (1) | SG177161A1 (da) |
SI (5) | SI2292636T1 (da) |
TN (1) | TNSN07069A1 (da) |
TW (1) | TWI372630B (da) |
WO (1) | WO2006031560A2 (da) |
ZA (1) | ZA200701626B (da) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1324776E (pt) * | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
HUE030579T2 (en) | 2003-04-04 | 2017-05-29 | Genentech Inc | High Concentration Antibody And Protein Products |
NZ589037A (en) | 2004-01-30 | 2011-10-28 | Shire Pharmaceuticals Ireland Ltd | Production and purification of recombinant arylsulfatase A |
WO2005112885A2 (en) | 2004-05-12 | 2005-12-01 | Baxter International Inc. | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
WO2005112894A1 (en) | 2004-05-12 | 2005-12-01 | Baxter International Inc. | Nucleic acid microspheres, production and delivery thereof |
US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
WO2007120449A1 (en) * | 2006-03-31 | 2007-10-25 | Genencor International, Inc. | Tangential flow filtration apparatuses, systems, and processes for the separation of compounds |
NZ623123A (en) | 2006-04-04 | 2015-04-24 | Zymenex As | A process for concentration of a polypeptide |
EP2142565A4 (en) | 2007-03-29 | 2010-03-31 | Abbott Lab | CRYSTALLINE HUMAN ANTI-IL-12 ANTIBODIES |
JP5432137B2 (ja) | 2007-07-17 | 2014-03-05 | エフ.ホフマン−ラ ロシュ アーゲー | 可変的タンジェンシャルフロー濾過 |
US20100249384A1 (en) * | 2007-11-29 | 2010-09-30 | Stefan Hepbildikler | Immunoglobulin aggregates |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
SG10201604258YA (en) * | 2007-11-30 | 2016-07-28 | Abbvie Biotechnology Ltd | Anti-tnf antibody formulations |
ES2406029T3 (es) | 2008-04-15 | 2013-06-05 | Grifols Therapeutics Inc. | Ultrafiltración/diafiltración en dos fases |
RU2010151414A (ru) * | 2008-05-15 | 2012-06-20 | В.Хэлт Л.П. (Bs) | Способ получения фракций молока, обогащенных секреторными иммуноглобулинами |
CA2744510A1 (en) * | 2008-12-09 | 2010-06-17 | F.Hoffmann-La Roche Ag | Method for obtaining an excipient-free antibody solution |
CA2750263C (en) * | 2009-01-21 | 2018-03-20 | Smartflow Technologies, Inc. | Optimization of separation for viscous suspensions |
WO2010102241A1 (en) * | 2009-03-06 | 2010-09-10 | Genentech, Inc. | Antibody formulation |
WO2010111378A1 (en) * | 2009-03-24 | 2010-09-30 | Wyeth Llc | Membrane evaporation for generating highly concentrated protein therapeutics |
EP2435474A2 (en) * | 2009-05-27 | 2012-04-04 | Baxter International Inc | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
HUE029197T2 (en) * | 2009-09-29 | 2017-02-28 | Hoffmann La Roche | Adjustment of dissolved buffer by pre-filtration to a high concentration immunoglobulin formulation |
AU2010302662B2 (en) | 2009-10-01 | 2015-11-26 | F. Hoffmann-La Roche Ag | Multistep final filtration |
PL2531218T3 (pl) | 2010-02-04 | 2019-05-31 | Csl Behring Ag | Preparat immunoglobuliny |
DK2542257T3 (da) | 2010-03-01 | 2017-10-16 | Bayer Healthcare Llc | Optimerede monoklonale antistoffer mod vævsfaktorvej-inhibitor (tfpi) |
EP2729566B1 (en) | 2011-07-08 | 2017-03-15 | Shire Human Genetic Therapies, Inc. | Methods for purification of arylsulfatase a |
CA2847302C (en) * | 2011-09-01 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
CN104955479A (zh) * | 2012-12-28 | 2015-09-30 | 诺和诺德股份有限公司 | 高温死端抗体过滤 |
CN104903442A (zh) | 2013-01-09 | 2015-09-09 | 夏尔人类遗传性治疗公司 | 含用于纯化芳基硫酸酯酶a的方法 |
DE102013001628A1 (de) | 2013-01-30 | 2014-07-31 | Fresenius Medical Care Deutschland Gmbh | Verfahren zur Bereitstellung eines Konzentrats |
BR112016025854B1 (pt) | 2014-05-13 | 2022-03-03 | Amgen Inc | Sistema de controle de processo; método de controle de processo para uso com uma ou mais unidades de processamento e processo para purificar uma proteína |
EP4144434B1 (en) * | 2014-06-16 | 2024-04-17 | EMD Millipore Corporation | Single-pass filtration systems and processes |
US10550148B2 (en) | 2014-06-16 | 2020-02-04 | Emd Millipore Corporation | Methods for increasing the capacity of flow-through processes |
US10207225B2 (en) * | 2014-06-16 | 2019-02-19 | Emd Millipore Corporation | Single-pass filtration systems and processes |
EP2957335B1 (en) * | 2014-06-16 | 2020-05-27 | EMD Millipore Corporation | Single-pass filtration systems and processes |
EP2986361B1 (en) | 2014-06-25 | 2019-06-12 | EMD Millipore Corporation | Compact spiral-wound membrane filter elements |
SG11201508664VA (en) | 2014-08-29 | 2016-03-30 | Emd Millipore Corp | Single Pass Tangential Flow Filtration Systems and Tangential Flow Filtration Systems withRecirculation of Retentate |
WO2016033553A1 (en) | 2014-08-29 | 2016-03-03 | Emd Millipore Corporation | Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate |
EA033444B1 (ru) | 2014-10-23 | 2019-10-31 | Amgen Inc | Снижение вязкости фармацевтических составов |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
EP3352790A1 (en) * | 2015-09-22 | 2018-08-01 | Pfizer Inc | Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method |
TWI767930B (zh) * | 2016-08-16 | 2022-06-21 | 美商健臻公司 | 處理包括重組治療性蛋白之流體的方法及其用途 |
CN110198952B9 (zh) * | 2016-08-17 | 2024-05-28 | 勃林格殷格翰国际公司 | 制备含有生物分子的高度浓缩的液体制剂的方法 |
EA201990998A1 (ru) | 2016-10-21 | 2019-11-29 | Фармацевтические составы и способы их получения | |
JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
CN107952280A (zh) * | 2017-11-28 | 2018-04-24 | 安徽东方帝维生物制品股份有限公司 | 一种兽用疫苗无菌超滤浓缩装置及方法 |
WO2019132418A1 (ko) * | 2017-12-27 | 2019-07-04 | ㈜셀트리온 | 투석 여과 방법 |
KR20210005053A (ko) * | 2018-04-12 | 2021-01-13 | 암젠 인크 | 안정한 단백질 조성물의 제조 방법 |
TWI846694B (zh) * | 2018-05-04 | 2024-07-01 | 美商健臻公司 | 具有過濾系統的灌注式生物反應器 |
US20210308265A1 (en) * | 2018-08-10 | 2021-10-07 | Amgen Inc. | Method of preparing an antibody pharmaceutical formulation |
KR20210044821A (ko) | 2018-08-14 | 2021-04-23 | 브리스톨-마이어스 스큅 컴퍼니 | 개선된 단백질 회수 |
TW202043253A (zh) * | 2019-01-28 | 2020-12-01 | 美商安進公司 | 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程 |
CN114144652A (zh) * | 2019-07-31 | 2022-03-04 | 康特伦英国斯温顿捷迪斯有限公司 | 用于药物制剂计量给药的密度流量计 |
CN111018968B (zh) * | 2019-12-16 | 2021-07-27 | 兴盟生物医药(苏州)有限公司 | 一种通过超滤浓缩制备高浓度抗体制剂的方法 |
JP7338527B2 (ja) * | 2020-03-19 | 2023-09-05 | 東レ株式会社 | 体液検体中のアレルゲン特異的IgE抗体の検出方法 |
CN111944046B (zh) * | 2020-08-28 | 2021-04-09 | 江苏荃信生物医药有限公司 | 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法 |
CN116406369A (zh) * | 2020-10-05 | 2023-07-07 | 百时美施贵宝公司 | 用于浓缩蛋白质的方法 |
EP4243966A1 (en) | 2020-11-23 | 2023-09-20 | Abec, Inc. | Filtration systems,components and methods |
CN114014929B (zh) * | 2021-11-04 | 2022-07-19 | 江苏荃信生物医药股份有限公司 | 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法 |
AU2023225043A1 (en) | 2022-02-25 | 2024-08-08 | Amgen Inc. | Methods of preparing high concentration liquid drug substances |
CN115261193A (zh) * | 2022-05-31 | 2022-11-01 | 利穗科技(苏州)有限公司 | 一种生物制品浓缩系统及其工艺 |
WO2024012364A1 (en) * | 2022-07-12 | 2024-01-18 | Beigene Switzerland Gmbh | Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df) |
US12030959B1 (en) | 2023-07-05 | 2024-07-09 | Genentech, Inc. | Anti-IgE antibody therapy for multiple food allergies |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5625616B2 (da) | 1973-10-08 | 1981-06-13 | ||
FR2459619B1 (fr) | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede |
US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IN161706B (da) | 1983-10-05 | 1988-01-16 | Solco Basel Ag | |
US4786501A (en) * | 1985-07-15 | 1988-11-22 | International Minerals & Chemical Corp. | Cylindrical implants for the controlled release of growth hormones |
US4756696A (en) | 1985-12-06 | 1988-07-12 | Amp Incorporated | Solder joint inspection feature for surface mount connectors |
GB8628104D0 (en) * | 1986-11-25 | 1986-12-31 | Connaught Lab | Pasteurization of immunoglobin solutions |
JPS6485829A (en) | 1987-09-29 | 1989-03-30 | Aisin Aw Co | Transmission for four-wheel drive vehicle |
JPH01268646A (ja) | 1988-04-20 | 1989-10-26 | Meiji Milk Prod Co Ltd | 抗腫瘍剤 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US4897465A (en) | 1988-10-12 | 1990-01-30 | Abbott Laboratories | Enrichment and concentration of proteins by ultrafiltration |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US5177194A (en) * | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
NL9001650A (nl) | 1990-07-19 | 1992-02-17 | Ver Coop Melkind | Werkwijze voor de bereiding van een melkeiwit-isolaat. |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5256294A (en) | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
JP2907603B2 (ja) * | 1991-09-09 | 1999-06-21 | 雪印乳業株式会社 | 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品 |
US6270757B1 (en) | 1994-04-21 | 2001-08-07 | Genetics Institute, Inc. | Formulations for IL-11 |
US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5707678A (en) | 1995-04-12 | 1998-01-13 | Galagen Inc. | Method for microfiltration of milk or colostral whey |
CA2761116A1 (en) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CN1151842C (zh) * | 1995-07-27 | 2004-06-02 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白制剂 |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
DE19543737A1 (de) | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
DK0942968T3 (da) | 1996-12-03 | 2008-06-23 | Amgen Fremont Inc | Fuldt humane antistoffer, der binder EGFR |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
EP1017286A4 (en) | 1997-09-22 | 2004-06-09 | Sepragen Corp | Successive separation of whey protein and formulations |
RU2140287C1 (ru) | 1998-08-25 | 1999-10-27 | Государственное унитарное предприятие "Иммунопрепарат" | Способ получения альбумина |
WO2000024266A2 (en) | 1998-10-26 | 2000-05-04 | Galagen, Inc. | Soy and immunoglobulin compositions |
UY26236A1 (es) | 1999-07-07 | 2000-10-31 | New Zeland Co Operative Dairy | Metodos para obtener aislados de proteina y concentrados de calostro |
ES2644275T3 (es) * | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
PT1324776E (pt) * | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
ES2184594B1 (es) | 2001-01-17 | 2004-01-01 | Probitas Pharma Sa | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. |
DE60237841D1 (de) * | 2001-11-13 | 2010-11-11 | Genentech Inc | Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung |
US20060182740A1 (en) * | 2002-06-21 | 2006-08-17 | Biogen Idec, Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
EP1596667B1 (en) * | 2002-11-01 | 2009-01-21 | Bayer HealthCare LLC | Process for the concentration of proteins |
GB0229444D0 (en) | 2002-12-18 | 2003-01-22 | Royal Free Hampstead Nhs Trust | Diagnostic method and assay kit |
EP1601788A4 (en) * | 2003-02-24 | 2006-11-15 | Gtc Biotherapeutics Inc | TANGENTIAL FILTRATION METHODS AND APPARATUS THEREFOR |
HUE030579T2 (en) | 2003-04-04 | 2017-05-29 | Genentech Inc | High Concentration Antibody And Protein Products |
US20070244305A1 (en) | 2004-01-30 | 2007-10-18 | Suomen Punainen Risti Veripalvelu | Process for The Manufacture of Virus Safe Immunoglobulin |
US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
JP6044754B2 (ja) | 2012-01-19 | 2016-12-14 | 株式会社ジェイテクト | クラッチプレートおよびその製造方法 |
-
2005
- 2005-09-06 US US11/220,362 patent/US20060051347A1/en not_active Abandoned
- 2005-09-07 MY MYPI20104600 patent/MY150549A/en unknown
- 2005-09-07 TW TW094130719A patent/TWI372630B/zh active
- 2005-09-07 MY MYPI20054224A patent/MY162525A/en unknown
- 2005-09-08 EP EP22178117.2A patent/EP4108259B1/en active Active
- 2005-09-08 EP EP10009914.2A patent/EP2292636B9/en active Active
- 2005-09-08 ES ES10009914T patent/ES2968070T3/es active Active
- 2005-09-08 ES ES22178117T patent/ES2975166T3/es active Active
- 2005-09-08 AU AU2005285243A patent/AU2005285243C1/en active Active
- 2005-09-08 HU HUE10009914A patent/HUE065025T2/hu unknown
- 2005-09-08 LT LTEP10009914.2T patent/LT2292636T/lt unknown
- 2005-09-08 KR KR1020127030933A patent/KR101528970B1/ko active IP Right Review Request
- 2005-09-08 LT LTEP22178156.0T patent/LT4104859T/lt unknown
- 2005-09-08 FI FIEP22178156.0T patent/FI4104859T3/fi active
- 2005-09-08 SI SI200532316T patent/SI2292636T1/sl unknown
- 2005-09-08 EP EP20200642.5A patent/EP3805248B1/en active Active
- 2005-09-08 SI SI200532312T patent/SI3805248T1/sl unknown
- 2005-09-08 DK DK05806393.4T patent/DK1786830T3/da active
- 2005-09-08 PT PT202006425T patent/PT3805248T/pt unknown
- 2005-09-08 FI FIEP22178117.2T patent/FI4108259T3/fi active
- 2005-09-08 PL PL10009914.2T patent/PL2292636T3/pl unknown
- 2005-09-08 JP JP2007531302A patent/JP5210633B2/ja active Active
- 2005-09-08 SI SI200532317T patent/SI4108259T1/sl unknown
- 2005-09-08 HU HUE22178117A patent/HUE067296T2/hu unknown
- 2005-09-08 SG SG2011088622A patent/SG177161A1/en unknown
- 2005-09-08 PT PT100099142T patent/PT2292636T/pt unknown
- 2005-09-08 DK DK22178117.2T patent/DK4108259T3/da active
- 2005-09-08 PT PT221781172T patent/PT4108259T/pt unknown
- 2005-09-08 DK DK10009914.2T patent/DK2292636T3/da active
- 2005-09-08 DK DK20200642.5T patent/DK3805248T5/da active
- 2005-09-08 FI FIEP20200642.5T patent/FI3805248T3/fi active
- 2005-09-08 CN CN2012103764183A patent/CN102911268A/zh active Pending
- 2005-09-08 PL PL22178117.2T patent/PL4108259T3/pl unknown
- 2005-09-08 FI FIEP10009914.2T patent/FI2292636T3/fi active
- 2005-09-08 EP EP22178156.0A patent/EP4104859B1/en active Active
- 2005-09-08 MX MX2012011125A patent/MX342788B/es unknown
- 2005-09-08 DK DK22178156.0T patent/DK4104859T3/da active
- 2005-09-08 PL PL20200642.5T patent/PL3805248T3/pl unknown
- 2005-09-08 CA CA2577317A patent/CA2577317C/en active Active
- 2005-09-08 PL PL22178156.0T patent/PL4104859T3/pl unknown
- 2005-09-08 WO PCT/US2005/031844 patent/WO2006031560A2/en active Application Filing
- 2005-09-08 CN CN200580038351.0A patent/CN101056885B/zh active Active
- 2005-09-08 LT LTEP22178117.2T patent/LT4108259T/lt unknown
- 2005-09-08 RU RU2007110534/13A patent/RU2390524C2/ru active
- 2005-09-08 ZA ZA200701626A patent/ZA200701626B/xx unknown
- 2005-09-08 HU HUE20200642A patent/HUE061899T2/hu unknown
- 2005-09-08 ES ES20200642T patent/ES2942574T3/es active Active
- 2005-09-08 SI SI200531932T patent/SI1786830T1/sl unknown
- 2005-09-08 EP EP05806393.4A patent/EP1786830B1/en not_active Revoked
- 2005-09-08 NZ NZ553239A patent/NZ553239A/en unknown
- 2005-09-08 ES ES22178156T patent/ES2983099T3/es active Active
- 2005-09-08 MX MX2007002812A patent/MX2007002812A/es not_active Application Discontinuation
- 2005-09-08 ES ES05806393.4T patent/ES2528541T3/es active Active
- 2005-09-08 PT PT221781560T patent/PT4104859T/pt unknown
- 2005-09-08 SI SI200532319T patent/SI4104859T1/sl unknown
- 2005-09-08 BR BRPI0515649A patent/BRPI0515649B8/pt active IP Right Grant
- 2005-09-08 KR KR1020077007862A patent/KR20070109975A/ko not_active Application Discontinuation
- 2005-09-08 PL PL05806393T patent/PL1786830T3/pl unknown
- 2005-09-08 CN CN201510468312.XA patent/CN104961797B/zh active Active
- 2005-09-08 LT LTEP20200642.5T patent/LT3805248T/lt unknown
- 2005-09-08 PT PT58063934T patent/PT1786830E/pt unknown
- 2005-09-09 PE PE2005001049A patent/PE20060816A1/es active IP Right Grant
- 2005-09-09 GT GT200500254A patent/GT200500254A/es unknown
- 2005-09-09 AR ARP050103779A patent/AR050641A1/es active IP Right Grant
-
2006
- 2006-09-29 US US11/537,577 patent/US20070237762A1/en not_active Abandoned
-
2007
- 2007-02-15 IL IL181372A patent/IL181372A/en active IP Right Grant
- 2007-02-23 TN TNP2007000069A patent/TNSN07069A1/en unknown
- 2007-02-28 EC EC2007007282A patent/ECSP077282A/es unknown
- 2007-03-16 NO NO20071432A patent/NO333660B1/no unknown
- 2007-04-06 MA MA29809A patent/MA28991B1/fr unknown
- 2007-06-27 HK HK07106910.7A patent/HK1101249A1/xx not_active IP Right Cessation
-
2009
- 2009-02-19 US US12/389,140 patent/US20090214522A1/en not_active Abandoned
-
2011
- 2011-11-24 JP JP2011256451A patent/JP5426641B2/ja active Active
- 2011-12-08 IL IL216851A patent/IL216851A0/en unknown
-
2014
- 2014-04-21 US US14/257,907 patent/US10370456B2/en active Active
-
2016
- 2016-04-05 HK HK16103797.1A patent/HK1215869A1/zh unknown
-
2020
- 2020-09-10 US US17/017,465 patent/US20210095050A1/en active Pending
-
2022
- 2022-11-01 US US17/978,913 patent/US11767370B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3805248T3 (da) | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf | |
DK3345927T3 (da) | Humant monoklonalt antistof Human CD134 (OX40) og fremgangsmåder til frembringelse og anvendelse deraf | |
DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
DK1853271T3 (da) | Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme | |
DK1679058T3 (da) | Farmaceutisk sammensætning til behandling af kardiovaskulære og cerebrovaskulære sygdomme | |
DK1756544T3 (da) | Diagnoseindretninger indeholdende fluider og fremgangsmåder til fremstilling | |
DK1641832T3 (da) | Fremgangsmåde til fremstilling af fiberholdig pektin og produkter og anvendelser heraf | |
DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
DK1844074T3 (da) | Humane antistoffer og proteiner | |
NO20033387L (no) | Modifiserte antistoffer og fremgangsmåter for anvendelse | |
DK1740197T3 (da) | Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki | |
DK1644021T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme | |
DK1965763T3 (da) | Stabile enzympræparater og fremgangsmåder til anvendelse heraf | |
DK1663298T3 (da) | Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner | |
DK1919290T3 (da) | Fremgangsmåder og produkter til behandling af sygdomme | |
DK1877090T3 (da) | Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf | |
IS8597A (is) | Samsetningar rísedrónats og aðferðir við notkun þess | |
DK2099796T3 (da) | Aza-indolyl-forbindelser og fremgangsmåder for anvendelse | |
DK2144555T4 (da) | Indretning og fremgangsmåde til transkutan bestemmelse af blodgasser | |
DK2617714T3 (da) | Kemiske derivater af jasmonat, farmaceutiske præparater og fremgangsmåder til anvendelse deraf | |
IS8497A (is) | Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma | |
DK1922309T3 (da) | N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf | |
DK1596868T3 (da) | Fremgangsmåde til behandling af hjertesvigt og medikament dertil | |
DK1862158T5 (da) | Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf | |
DK1768489T3 (da) | Apparat og fremgangsmåde til destruktion af vegetation |